secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunovant, Inc. (IMVT)
CIK:        0001764013
Form:       8-K
Filed at:   2022-08-05T23:59:59+00:00
Accession:  0001764013-22-000083
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunovant Q1 net loss $40.4M; initiates pivotal MG trial, TED trials on track
------------------------------------------------------------------------------

- Net loss of $40.4M ($0.35/share) vs $30.5M ($0.31) YoY; R&D expenses up to $28.4M from $18.7M.
- Cash $427M as of June 30; expects runway into calendar 2025 despite $31M in CMC/clinical payments in Q1.
- Pivotal batoclimab trial in Myasthenia Gravis initiated June 2022; top-line data expected H2 2024.
- FDA alignment on two pivotal trials in Thyroid Eye Disease; trials to start H2 2022, data H1 2025.
- Investor call Sep 7 to announce two new batoclimab indications and third pivotal trial for 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1764013/000176401322000083/0001764013-22-000083-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1764013/000176401322000083/imvt-20220805.htm
  HTML page:      https://secwatch.observer/filing/0001764013-22-000083

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer